Jump to content
Sclero Forums

Search the Community

Showing results for tags 'lupus complications'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 14 results

  1. Heart failure (HF) risk in systemic lupus erythematosus (SLE) compared to diabetes mellitus (DM) and general medicaid patients. Further investigation into the biologic mechanism of HF among SLE compared to non-SLE and DM patients may shed light on the findings of this study. PubMed, Semin Arthritis rheumatologist, 06/11/2019. (Also see Symptoms and Complications of Lupus and Symptoms and Complications of Diabetes) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Complement alternative pathway activation associated with pulmonary hypertension in lupus nephritis patients. Activation of the complement alternative pathway may be involved in the pathogenesis of pulmonary hypertension in lupus nephritis. PubMed, Lupus, 2019 Jul 11:961203319860192. (Also see Symptoms and Complications of Lupus and Pulmonary Hypertension) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Septic shock among patients with systemic lupus erythematosus (SLE): short and long–term outcome. Analysis of a French nationwide database. Septic shock is a frequent and severe complication among SLE patients even if it is not associated with more healthcare use than another episode of same severity. PubMed, J Infect, 04/08/2019. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles. 
  4. Metabolic syndrome (MetS) in patients with systemic lupus erythematosus: Association with disease activity, disease damage and age. The frequency of MetS was not significantly different from that of the control group, but almost half of the patients were found with this syndrome. PubMed, Int J rheumatologist Dis, 04/03/2018. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events. A high rate of endothelial dysfunction and vascular stiffness occurs in early lupus patients without cardiovascular risk factors and disease. PubMed, Arthritis Care Res (Hoboken), 12/15/2017. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Cerebrovascular Events (CerVEs) in Systemic Lupus Erythematosus (SLE). CerVEs, the fourth most frequent neuropsychiatric event in SLE, are usually attributable to lupus. PubMed, Arthritis Care Res (Hoboken), 01/05/2018. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. A retrospective study of joint infections in patients with systemic lupus erythematosus (SLE). When an SLE patient presents with pre–existing arthritis and suddenly develops asymmetric oligo– or large–joint swelling and pain with elevated C-reactive protein levels and low disease activity, joint infections should be considered. PubMed, Clin Rheumatol, 07/08/2017. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Comorbidities in patients with Primary Sjögren's Syndrome (pSS) and Systemic Lupus Erythematosus (SLE): A comparative registries–based study. pSS patients have consistently less serious cardiovascular comorbidity burden and a lower prevalence of severe infection than those with SLE, although in contrast, their risk of lymphoma was greater. PubMed, Arthritis Care Res (Hoboken), 08/26/2016. (Also see Sjögren's Syndrome and Lupus in Overlap and Complications) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Prognostic significance of platelet count in SLE patients. It was concluded that platelet count has a negative correlation with disease activity in SLE patients, and it should be considered as a prognostic factor, identifying patients with aggressive disease course. PubMed, Platelets, 2016 Sep 2:1-5. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. How compelling are the data for Epstein–Barr virus (EBV) being a trigger for systemic lupus (SLE) and other autoimmune diseases? Collectively, the interplay between an impaired immune system and the cumulative effects of EBV and other viruses results in frequent reactivation of EBV and enhanced cell death. PubMed, Curr Opin Rheumatol, 2016 Jul;28(4):398-404. (Also see Lupus in Overlap and Complications) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients. The present study provides possible links between intrarenal T cells, osteopontin, macrophages with reduced podocyte–nephrin and podocytopathy in systemic lupus erythematosus. PubMed, Lupus, 05/04/2016. (Also see Symptoms and Complications of Lupus and B Cells and T Cells) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Anti–Sm is associated with the early poor outcome of lupus nephritis. Our data suggest that anti–Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy–proven lupus nephritis during the follow–up period. PubMed, Int J rheumatologist Dis, 04/29/2016. (Also see Symptoms and Complications of Lupus and Antibodies in Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Risk of end–stage renal disease (ESRD) in systemic lupus erythematosus (SLE) patients: a nationwide population–based study. ESRD is more common in SLE than non–SLE patients in this insurance database. Wiley Online Library, 02/10/2016. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. Predictors of clinical outcomes in patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Patients with longer disease durations of SLE and those with more than one NPSLE symptom types had poorer outcomes. ScienceDirect, 01/07/2016. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...